Nasdaq

Intec Pharma Reports Fourth Quarter and Year End 2019 Financial Results and Corporate Update

"We entered 2020 with a focused agenda for leveraging our Accordion Pill platform in both the near- and long-term, with goals to outlicence our late-stage Parkinson's disease program, to advance our ...
MarketWatch

Intec stock plunges 80% after late-stage failure of Parkinson's drug

Shares of biotech Intec Pharma Ltd. plunged 80% in premarket trade Monday after the company said its late-stage trial of a drug meant to treat symptoms of advanced Parkinson's disease did not result ...
Reuters

Israel's Intec Pharma eyes revenue from Parkinson's drug in 2019

TEL AVIV (Reuters) - Israel's Intec Pharma, which is conducting a late stage trial for its long-lasting pill to treat Parkinson's disease, expects to start earning money from the program sometime in ...
Reuters

Intec Pharma - Plan To Initiate A PK Study Of AP-Cannabidiol (CBD) In First Half Of 2019

* INTEC PHARMA - TOGETHER WITH NOVARTIS CO HAS AGREED TO PROCEED WITH ACCORDION PILL PROGRAM, PLANS TO ENTER CLINIC WITH A FIRST-IN-HUMAN PK STUDY IN FIRST HALF OF 2019 Source text for Eikon: Further ...
Nasdaq

Intec Pharma to Participate in the HC Wainwright Global Life Sciences Conference

Mr. Meckler's presentation will be webcast live and will be accessible through the Events section of Intec Pharma's website at www.intecpharma.com, where it will also be archived for a period of time.